Luca Lo Nigro, MD, PhD

I was born in Catania (Italy), on September 18th, 1968. During university medical school, in Catania, I loved biology. This was the first step towards the type of medical doctor I dreamed to become. In fact, I realized that I would spend my life to be a doctor translating experiences and data from the bench to the bedside. In particular, I decided to work with the most important people representing our future: children. I also decided to focus my study on “the disease of the Century”: cancer VSports app下载. For this reason, I spent 6 months in Philadelphia, at Children’s Hospital (CHOP - 1992) focusing my medical degree-thesis on “p53 mutations in Li Fraumeni Syndrome”. A sign of destiny: one of the most severe cancer-predisposing syndromes in children. Moreover, I worked on minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) in Monza (1995), at professor Biondi’s lab, witnessing one of the most translational achievement in pediatric hemato-oncology. Furthermore, during my PhD, I spent several years working at CHOP (professor Carolyn Felix Lab) on KMT2A gene, formerly known Mixed Lineage Leukemia (MLL). Clinical impact and molecular characterization of MLL-rearrangements are still a debating object. Moreover, during the last 10 years I build up my own lab identifying several lines of research: 1-) characterization of Fanconi Anemia DNA repair system in children with Acute Leukemias; 2-) identification of specific pathways in acute leukemias using a phospho-flow (flow-cytometry FCM) approach; 3-) characterization of bone marrow microenvironment in children with acute leukemias;4-) familial leukemia and the leukemia predisposition; 5-) identification of children with ALL and Noonan Syndrome: a COST-LEGEND project. Laboratory and a long patient-a-side clinical experiences allow me to be the local principal investigator of national (AIEOP) and international (BFM, EsPhALL, Interfant) ALL protocols. Within AIEOP (Italian association of pediatric hemato-oncology), I am the elected coordinator of the Molecular and cellular Biology Working groups; and I am also an elected member of the following scientific working groups: ALL, NHL, new drugs, HSCT. Within BFM family, I am a member of ALL, AML, Biology&Diagnosis and Host Genome Variation committees, respectively. Finally, I am an active member of the following international scientific society: American Society of Hematology (since 2001), ASCO, AACR, BFM, SIOPeurope, and COST-LEGEND. .

I strongly believe that once we will well-characterize genes and pathways involved in cancer-predisposing syndrome, we will be able to better fight these terrible diseases, harnessing our knowledges and maybe, in the next future, arriving to prevent the disease onset. V体育官网.

International References: 95 articles with impact factor; 110 abstracts; H-Index: 31.

Editorial Board (Pediatric Oncology)
Terms of Appointment: August 2020 - July 2022;  August 2022 - July 2024;  August 2024 - July 2026